The bankruptcy of Cyxone AB

Cyxone AB (“the Company”), org nr. 559020-5471, was declared bankrupt on December 9, 2024. The lawyer Johan Klåvus, Trägårdh Law Firm, has been appointed bankruptcy trustee. Associate lawyer Matilda Gradén assists with the handling of the bankruptcy.

The Company’s business idea has been to develop “first-in-class” medicines which intends to slow down and halt the progression of severe autoimmune diseases such as multiple sclerosis, MS, and rheumatoid arthritis, RA, and also limit side effects of the diseases.

By the time of the bankruptcy the Company had two ongoing pharmaceutical projects, Rabeximod and T20K, which targets RA and MS respectively. Rabeximod has undergone the first stage (a) of a clinical phase 2-study but is ready for the second stage (b). So far Rabeximod has shown no side effects at therapeutic dose and has a confirmed efficacy in the study with 225 patients.

The Company’s business, including all property belonging to and owned by the Company, is hereby offered for sale.

The Company’s assets primarily consist of intellectual property such as patents, domain name, trademark and logo.

If you are interested in the business and/or assets, then please contact us, preferably by e-mail, matilda.graden@tragardh.se.